Fig. 3

LS mean change from baseline in SF-36 individual domains by visit in A MTX-naïve patients, filgotinib dosing regimens compared with MTX: B MTX-IR patients, and filgotinib dosing regimens compared with placebo and adalimumab C bDMARD-IR patients, filgotinib dosing regimens compared with placebo. Concentric octagons represent the LS mean change from baseline in the SF-36 domain score. Comparison with placebo or MTX: ^***P < 0.001, ^**P < 0.01, ^*P < 0.05. Comparison with ADA: ^†††P < 0.001, ^††P < 0.01. All P values are exploratory (not adjusted for multiplicity) and were from the MMRM including treatment, visit (as categorical), treatment by visit, stratification factors, baseline value as fixed effects, and patients being the random effect. In the MTX-IR study, patients receiving PBO were rerandomized to FIL 200 or 100 mg at week 24. The bDMARD-IR study ended at week 24. ADA, adalimumab; BP, bodily pain; bDMARD, biologic DMARD; csDMARD, conventional synthetic DMARD; DMARD, disease-modifying antirheumatic drug; FIL, filgotinib; GH, general health; LS, least-squares; MH, mental health; MMRM, mixed-effects model for repeated measures; MTX, methotrexate; PBO, placebo; PF, physical functioning; R-E, role-emotional; R-P, role-physical; SF, social functioning; SF-36, Medical Outcomes Study 36-Item Short Form; V, vitality